Halozyme Company Description
Halozyme Therapeutics makes enzymes for therapeutic and drug delivery applications. The company's products are based on recombinant human PH20, a human synthetic enzyme it hopes will offer safety benefits over animal-derived versions. The firm's first commercial product, Cumulase, is used for in-vitro fertilization. Another product, Hylenex, is used as an adjuvant for drug and fluid infusions. Products under development include drug delivery agents using the company's Enhanze technology, as well as therapeutic enzymes for cancer, metabolism, and dermatology applications. Halozyme's development partners include Roche and Baxter International.
View the Comprehensive Company Description for Halozyme
The Company Description provides a historical perspective of Halozyme's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Halozyme's evolution in the marketplace.
